Neurology Account Specialist

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) short interest update. August 29, 2026 Key points. * Short interest fell 49.6% to 3,812 shares as of August 14, representing effectively 0.0% of shares outstanding and a 0.0-day short-interest ratio. * Shionogi reported quarterly EPS of $0.36, beating estimates of $0.18, while revenue of $1.04 billion exceeded the $970.69 million consensus forecast. * Analyst sentiment improved, with Jefferies and Goldman Sachs upgrading the ADR to "strong buy"; MarketBeat lists an overall average rating of "Buy." * MarketBeat previews top five stocks to own in September. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 3,812 shares, a decline of 49.6% from the July 30th total of 7,564 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 150,205 shares, the short-interest ratio is currently 0.0 days. Shionogi & Co., Ltd. Unsponsored ADR stock down 0.6%. Shares of SGIOY stock opened at $9.04 on Friday. Shionogi & Co., Ltd. Unsponsored ADR has a one year low of $7.65 and a one year high of $12.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46. The stock has a fifty day moving average price of $8.85 and a 200 day moving average price of $9.76. The stock has a market cap of $15.39 billion, a P/E ratio of 9.04, a price-to-earnings-growth ratio of 3.36 and a beta of 0.08. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.47%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. Analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 earnings per share for the current year. Institutional inflows and outflows. An institutional investor recently bought a new stake in Shionogi & Co., Ltd. Unsponsored ADR stock. Birmingham Capital Management Co. Inc. AL purchased a new position in shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,950 shares of the company's stock, valued at approximately $257,000. Hedge funds and other institutional investors own 1.92% of the company's stock. Analysts set new price targets. Several research firms recently commented on SGIOY. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 14th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "strong sell" rating to a "hold" rating in a report on Monday, May 25th. Finally, The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy". Discover more Options Profit Calculator AI Infrastructure Stocks Stock Split Calculator Shionogi & Co., Ltd. Unsponsored ADR company profile. Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders. The company's product portfolio spans both established and innovative therapies. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list. While Shionogi & Co., Ltd. Unsponsored ADR currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

StreetAccount summary - asian market recap: Nikkei +3.66%, Hang Seng +0.24%, Shanghai Composite +1.47% as of 04:10 ET. Aug 05 ,2026 * Synopsis: * Asia equities rallied almost everywhere for a second consecutive day Wednesday. Technology-leaning benchmarks in South Korea, Taiwan and Japan saw the sharpest gains, while Shenzhen outperformed in mainland China. Hong Kong and Shanghai saw more modest gains while Australia's ASX reached a fresh record high. India has pared early gains while Southeast Asia is mixed. US futures higher, Europe opened with modest gains. US dollar unchanged, NZD slipped after strong jobs data, yuan and yen flat. Treasuries mixed, JGB yields lower, IGBs unchanged following RBI decision. Precious metals rallying with gold at a two-month high. Crude futures seeing more declines as Brent falls below $79/bl. Base metals higher again. Cryptocurrencies mixed. * Asia equities rallied further Wednesday following the overnight surge on Wall Street that took the S&P 500 to a fresh record high, and as futures indicate another strong open this morning in the US. SpaceX's after-hours share price decline unlikely to dissuade the bulls who received support overnight from Treasury Secretary Bessent who said a deal with Iran was imminent and an Axios report that said the US, Iran and Oman would announce an agreement to reopen the Strait of Hormuz later today. Asia equities received a further boost as the dollar remained at six-week lows, boosting local currencies and providing an additional tailwind. * In other developments, China's RatingDog Services PMI declined by more than expected and service growth in Japan also slowed; Singapore full PMI expanded further as new orders and output expanded further. Japan real wages rose for a sixth consecutive month. India's central bank kept its repo rate steady, raised its FY GDP growth forecast and lowered inflation projections but warned over risks to both forecasts from weather and geopolitical developments. * Zhongji Innolight (3308.HK) shares under pressure on a report saying the US was drafting a ban on the import of China-made optical receivers. Shein (+SHEIN) is targeting a $30-40B valuation in its Hong Kong IPO later this month, sources told Reuters. CXMT (688825.CH) is set to produce smartphone memory chips on par with industry's best, according to sources cited by Bloomberg. Shionogi's (4507.JP) CEO said the company is actively pursuing at least three acquisitions, and is considering an expansion in the US. Wistron (3231.TT) says AI server demand remains strong as quarterly profits more than double. Coupang (CPNG) posted a net quarterly loss following fines connected to its massive data breach last November. Samsung Electronics (005930.KS) and SK Hynix (000660.KS) are testing China-made chip tools as hedge against US risk, according to a Reuters report. * Digest: * Notable Gainers: * +24.5% 4062.JP (IBIDEN): reports Q1 results; revenue and operating profit beat FactSet estimates; raises FY guidance * +8.1% 669.HK (Techtronic Industries): reports H1 results * +5.0% 3034.TT (Novatek Microelectronics): reports Q2 EPS NT$10.40 vs FactSet NT$7.93 * +4.7% 9434.JP (SoftBank Corp): reports Q1 results; revenue and operating profit beat StreetAccount estimates * +4.0% 5401.JP (NIPPON STEEL): reports Q1 results; revenue and business profit beat FactSet estimates * +3.8% 196170.KS (Alteogen): signs exclusive license agreement for ALT-B4 * +1.8% 017670.KS (SK Telecom): reports Q2 results; operating profit beats StreetAccount estimates * Notable Decliners: * -6.8% 293490.KS (Kakao Games): reports Q2 results; revenue misses FactSet estimates * -6.3% 6367.JP (DAIKIN INDUSTRIES): reports Q1 results; net income misses FactSet estimates * -5.1% 4980.JP (Dexerials): reports Q1 results; revenue below FactSet estimates * -3.4% 3064.JP (MonotaRO): reports H1 results * Data: * Economic: * China July * July RatingDog Services PMI 50.4 vs consensus 53.7 and 54.1 in prior month * Composite PMI 50.8 vs 53.6 in prior month * India July * Final services PMI 53.3 vs flash 53.1 and 57.4 in prior month * Composite PMI 54.3 vs flash 54.3 and 57.1 in prior month * Japan * June average nominal wages +3.4% y/y vs consensus +3.4% and revised +3.3% in prior month * Real wages +1.6% y/y vs consensus +1.6% and revised +1.6% in prior month * July final services PMI 51.2 vs flash 51.9 and 52.2 in prior month * Composite PMI 52.7 vs flash 53.1 and 52.8 in prior month * New Zealand Q2 * Employment +0.5% q/q vs consensus +0.1% and revised +0.1% in Q1 * Unemployment rate 5.6% vs consensus 5.4% and 5.3% in Q1 * Singapore June * Retail sales y/y +4% versus +2.9% in prior month * Markets: * Nikkei: 2,342.91 or +3.66% to 66300.44 * Hang Seng: 62.90 or +0.24% to 25915.82 * Shanghai Composite: 56.15 or +1.47% to 3878.43 * Shenzhen Composite: 51.45 or +2.07% to 2537.55 * ASX200: 82.00 or +0.90% to 9227.80 * KOSPI: 239.31 or +3.76% to 6598.26 * SENSEX: (19.38) or (0.02%) to 78409.57 * Currencies: * $-¥: +0.01 or +0.01% to 157.7490 * $-KRW: (4.12) or (0.29%) to 1425.6000 * A$-$: +0.00 or +0.01% to 0.7046 * $-INR: (0.01) or (0.01%) to 95.1646 * $-CNY: (0.00) or (0.07%) to 6.7485

Shionogi launches XOCOVA in the U.S. for prevention of COVID-19 following exposure. Wednesday, July 29, 2026 Shionogi has announced the U.S. availability of XOCOVA(R)(ensitrelvir), the first and only oral antiviral approved to help prevent COVID-19 after exposure. The treatment is indicated for adults and adolescents aged 12 years and older who have been in contact with someone infected with COVID-19 and is now available through the company's U.S. subsidiary, Shionogi Inc. XOCOVA works by blocking viral replication during the period between exposure to the virus and the onset of symptoms. The treatment is taken once daily for five days, beginning with a loading dose of 375 mg on the first day, followed by 125 mg once daily on days two to five. It should be started as soon as possible and within 72 hours of exposure to an infected individual. The launch comes as health authorities continue to monitor seasonal increases in COVID-19 cases in the United States. The company highlighted that post-exposure prophylaxis is an established approach used for other infectious diseases and may help reduce the burden of COVID-19 by preventing infection after exposure. Shionogi is supporting the commercial rollout of XOCOVA through healthcare professional and public education programmes, alongside partnerships with national and regional pharmacy networks to improve product availability across the United States. The company is also offering a co-pay assistance programme for eligible commercially insured patients to help reduce out-of-pocket costs. For the U.S. market, all stages of XOCOVA manufacturing, including active pharmaceutical ingredient production, drug formulation, packaging, quality control, release testing, supply chain management and distribution, are carried out within the United States.